AtaCor Medical, Inc.
AtaCor Medical is committed to advancing the standard of care in cardiac rhythm management by designing innovative extravascular pacing and defibrillation leads. Their mission is to help physicians restore rhythm and preserve life through novel solutions that eliminate the risks, costs, and drawbacks of traditional transvenous leads.
Industries
Nr. of Employees
small (1-50)
AtaCor Medical, Inc.
Patents
Products
Extravascular temporary pacing lead system
An implantable temporary pacing lead system designed to provide reliable pacing support without entering the heart or vascular system, delivered via a parasternal approach and intended for fluoroscopy-free deployment.
Extravascular ICD lead system
An extravascular lead system developed to provide reliable sensing, antitachycardia pacing (ATP), and defibrillation shocks without transvenous lead placement, implanted via a parasternal approach and engineered for use with existing ICD pulse generators.
Extravascular temporary pacing lead system
An implantable temporary pacing lead system designed to provide reliable pacing support without entering the heart or vascular system, delivered via a parasternal approach and intended for fluoroscopy-free deployment.
Extravascular ICD lead system
An extravascular lead system developed to provide reliable sensing, antitachycardia pacing (ATP), and defibrillation shocks without transvenous lead placement, implanted via a parasternal approach and engineered for use with existing ICD pulse generators.
Expertise Areas
- Cardiac rhythm management device development
- Extravascular lead engineering
- Temporary and implantable pacing system design
- Extravascular defibrillation (ICD) therapy development
Key Technologies
- Extravascular implantable leads
- Parasternal/substernal delivery systems
- Temporary pacing lead technology
- Antitachycardia pacing (ATP) capability
News & Updates
Study marks the first permanent implantation of the company's EV-ICD Lead System for the treatment of life-threatening ventricular tachyarrhythmias
Funding supports regulatory submissions and clinical milestones.
Presentation of results from EV-ICD studies.
Presentation of preliminary results from first-in-human EV-ICD study.
Recognition for innovation in 2021.
Study results support the feasibility of AtaCor's extravascular pacing system.
Study marks the first permanent implantation of the company's EV-ICD Lead System for the treatment of life-threatening ventricular tachyarrhythmias
Funding supports regulatory submissions and clinical milestones.
Presentation of results from EV-ICD studies.
Presentation of preliminary results from first-in-human EV-ICD study.
Recognition for innovation in 2021.
Study results support the feasibility of AtaCor's extravascular pacing system.